Overcoming Drug Resistance Patterns in Non-Responders: Proven Best Practices on Informing Your Clinical Strategy

Many standard of care (SOC) treatments in cancer patients result in a clinical outcome of non-response. Drug development companies are trending toward interrogating resistance mechanisms and using this information in advancing their programs and informing personalized approaches to novel therapeutics.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Complementary Detection of Somatic Variants from Tumor Tissue and Plasma Samples Using AVENIO Analysis Kits

ROCHE

The AVENIO Tumor Tissue Targeted Kit is a next-generation sequencing (NGS) assay for comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. It contains 17 guideline-aligned biomarkers, including those in the U.S. National Comprehensive Cancer Network (NCCN).
Watch Now

Making Oral solid dosage forms with galenIQ™ - the sweet-tasting filler binder

During direct compression tablets are manufactured without pre-granulation. Excipients therefore need to be highly effective, controllable and free-flowing.
Watch Now

The science of smarter sampling for drug development

Neoteryx

On Tuesday, June 25th, at 10:00 AM EDT, 4:00 PM CEST, Neoteryx, The Medicine Maker, and two leading blood microsampling experts present The Science of Smarter Sampling for Drug Development, an in-depth hour-long webinar covering the details of how to succeed with blood microsampling technology in the analytical lab.
Watch Now

Maximizing the Value of Your Drug Development Program

questexweb

This webinar will benefit executives at Biotech and Pharmaceutical companies interested in learning more about 505(b)(2) drug development and how to save time and money while maximizing the value of their drug development program.
Watch Now

Spotlight

resources